Clover Health announced a public offering of Class A common stock that will bring about $300 million of gross proceeds to be used mainly for working capital and general corporate purposes. This is making the intrinsic value of CLOV stock worse, which is bad news for investors. I estimate that unless Clover Health finds a way to make its business model work, its goal to reach profitability in 2022 is too ambitious and unrealistic.